Dementia and Alzheimer Disease

A best-case analysis indicated that, for amyloid-positive patients diagnosed with MCI due to AD or mild AD dementia, lecanemab plus standard of care provided an additional gain of 0.75 in quality-adjusted life years.

Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.

Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.

The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 22, 2022.

The neurologist and assistant professor at the University of Toronto provided insight on the differences between outcome measures for Alzheimer disease and how they factored into a new item-level analysis of aducanumab (Aduhelm; Biogen). [WATCH TIME: 3 minutes]

BioArctic CEO Gunilla Osswald, PhD, called the decision disappointing but noted that phase 1 data are supportive of ABBV-0805’s progression to phase 2 and that the company would “investigate options to continue the development” of the α-synuclein antibody.

Outcomes in TBI admission survivors at 24 months—including mortality, development of posttraumatic epilepsy, and use of antiseizure medications—were poorer for cases with early posttraumatic seizures after adjustment for confounders.

The neurologist and assistant professor at the University of Toronto detailed findings from a new analysis that supports meaningful treatment effect with aducanumab in Alzheimer disease. [WATCH TIME: 6 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed what high-potential repurposed medications could be an option to treat symptoms of COVID-19 and the realistic possibility of clinical trials. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

When controlling for insulin and body mass index, the association between physical activity and cerebral glucose metabolism remained unchanged, while the association with gray matter volume was lost.

Neurology News Network for the week ending April 16, 2022 [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 15, 2022.

In addition to demonstrating significant differences in slowing functional decline, those on gamma sensory stimulation also demonstrated a significant reduction in brain atrophy relative to the sham group in the OVERTURE study.

The assistant professor of neurology at the University of Pennsylvania discussed stroke risk among patients with COVID-19 and the need to seek neurological consultation. [WATCH TIME: 3 minutes]

Adverse events were balanced across treatment and placebo groups, with no observed treatment-associated elevations in cerebrospinal fluid white blood cell counts or protein.

The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and associations with neurodegenerative disorders. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 8, 2022.